FDA Authorizes Sonovein Device for Varicose Veins
The noninvasive focused ultrasound platform treats great saphenous vein reflux, the main cause of varicose veins.
Updated on Nov. 16, 2026 in Stroke

Live Poll
Do you think varicose vein treatment is getting better for patients?
The FDA granted De Novo authorization to Theraclion's Sonovein device for treating varicose veins, announced November 16, 2026. The device is the first noninvasive focused ultrasound platform for this use, requiring no incisions or catheters.
Why it matters
Varicose veins affect approximately one third of adults, and the authorization offers a treatment option that avoids incisions and catheters. The decision follows a pivotal trial showing high vein occlusion rates with few adverse events.
The VEINRESET pivotal trial enrolled 70 participants across four sites in the US and Europe and achieved a 96.8% great saphenous vein occlusion rate after one year. Only one mild adverse event was observed, and no serious or unanticipated adverse events were reported, though the small sample leaves long-term outcomes unassessed.
The players
Theraclion
Theraclion is a medical device company that developed the Sonovein focused ultrasound platform for treating varicose veins.
The details
The authorization covers treatment of superficial venous reflux in the great saphenous veins, the main cause of varicose veins. Theraclion plans to establish reference treatment centers and physician training programs, and has created a dedicated Category III CPT code as an initial step toward insurance coverage.
Timeline
November 16, 2026: Theraclion announces FDA De Novo authorization of Sonovein.
Health Landscape
Sonovein's De Novo authorization follows the FDA's pathway for novel devices without a predicate, which is why it was not cleared through the faster 510(k) route used for devices similar to existing products. The authorization positions noninvasive focused ultrasound as a new category alongside traditional endovenous laser and radiofrequency ablation treatments for venous disease.
Patients with varicose veins may gain access to a treatment that requires no incisions or catheters once physicians are trained and treatment centers open. Availability will depend on physician adoption and insurance coverage, which Theraclion has begun pursuing through a Category III CPT code.
The takeaway
Varicose veins are common, and a noninvasive option may broaden treatment choices for patients who want to avoid surgery. Patients should ask their physicians whether focused ultrasound is appropriate once it becomes available locally.
Further reading
Explore more on Stroke to see how vascular conditions connect to broader circulatory health.
Source note: This article includes information reported by News-Medical.
Live Poll
Do you think varicose vein treatment is getting better for patients?










